Evaluation of clinical outcomes in systemic juvenile idiopathic arthritis patients treated with biological agents in Turkey: the TURSIS study
Authors' conclusion
The results of our study support the efficacy of biological drugs in particular anti-IL-1 and anti-IL-6 drugs, in the treatment of SJIA. These treatments resulted in improvement in activity of disease and provide a considerable decrease in the frequency of MAS.
Study context
- Population
- Patients with sJIA in whom a biological treatment was initiated between 1st March 2013 and 30th December 2018, Turkey
- Participants
- 147 patients
- Exposure
- Biological agents in sJIA
- Outcome
- Efficacy and safety of biological drugs
- Follow-up
- 24 months
Methodological detailsmulticentre, 24-month follow-up
- Multicentre
- 24-month follow-up
Main finding
As reported in the abstract
First-choice biologic
- Better PGA scores with anakinra at Month 3 vs other treatments
- P = 0.04
Observational data: associations, not effects.
Further findings
Clinical course of disease
- Monocyclic
- 38.1%
- Polycyclic
- 49%
- Persistent
- 12.9%
Biologic choice by subgroup
- Anakinra most preferred in macrophage activation syndrome (MAS)
- P = 0.000
- Tocilizumab used more frequently in persistent type
- P = 0.003
Switch rate
- Switched from anakinra (most frequent)
- n=40/68, 58.8%
- Anakinra switches to canakinumab
- n=32/40, 80%
Original publication
Evaluation of clinical outcomes in systemic juvenile idiopathic arthritis patients treated with biological agents in Turkey: the TURSIS study. Clin Exp Rheumatol. Published 3 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →